| 发明名称 | Use of dihydroimidazolones for the treatment of dogs | ||
| 摘要 | The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs. | ||
| 申请公布号 | US8859540(B2) | 申请公布日期 | 2014.10.14 |
| 申请号 | US200711879708 | 申请日期 | 2007.07.18 |
| 申请人 | Boehringer Ingelheim Vetmedica GmbH | 发明人 | Rundfeldt Chris;Dost Rita;Loscher Wolfgang;Tipold Andrea;Unverferth Klaus;Lankau Hans-Joachim |
| 分类号 | A61K31/535;A61K31/41 | 主分类号 | A61K31/535 |
| 代理机构 | Fulbright & Jaworski LLP | 代理人 | Fulbright & Jaworski LLP ;Crawford James R. |
| 主权项 | 1. A method for treating a behavioral abnormality in a dog wherein the behavioral abnormality is anxiety, comprising administering to a dog suffering from said anxiety an amount of from 5 to 30 mg/kg of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H imidazol-1-2-one or a physiological salt thereof once daily to alleviate said anxiety. | ||
| 地址 | Ingelheim DE | ||